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can previous treatment with beta-blockers attenuate myocardial 
dysfunction in patients with Tako-Tsubo cardiomyopathy?
IntRODuCtIOn: Tako-Tsubo cardiomyopathy (TTC) is a clinical condition characterized by acute and gener-
ally reversible myocardial dysfunction. It is usually triggered by significant emotional or physical stress. Catecho-
lamine activation of adrenoceptors has been recognized as a primary trigger of pathophysiological changes in 
TTC1. Previous data showed no evidence that cardioprotective drugs such as beta-blockers (BB) decrease reoccur-
rence of TTC2. We sought to evaluate whether chronic BB therapy attenuates myocardial dysfunction and type of 
wall motion abnormalities (WMA) in patients presenting with TTC. 
MethODs: We retrospectively analyzed medical record data of patients admitted with TTC from January 2011 to 
March 2015. Left ventricular ejection fraction (LVEF), location and extent of MWA were compared between patients 
previously treated with BB and patients without a BB in therapy at admission. 
Results: Twenty-one patient with TTC was identified. Nine patients were BB users and eleven patients were BB 
non-users. Information on previous BB therapy was not available for one patient who was excluded from the analy-
sis. There was no significant differences in demographic and clinical data between study groups. No statistically 
significant difference in LVEF and forms of WMA was found between study groups (0.425 and 1.000, respectively) 
(Table 1). 
COnClusIOn: Results indicate that previous use of BB does not attenuate the severity of myocardial dysfunc-
tion nor the type of WMA in patients presenting with TTC. These results warrant further investigation and confir-
mation on a larger number of patients. Time of patient presentation and echocardiographic examination should 
also be considered in the analysis.
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TAbLe 1. Patients’ data.
BB users (N=9) BB non-users (N=11) p
Age, mean (min-max) 63.56 (33-79) 60.09 (45-76) 0.617
Women, n 8 7 0.319
















LVEF, mean (SD) 47.22 (14.1) 42.27 (12.9) 0.425
BB – beta-blocker; LVEF – left ventricular ejection fraction; SD – standard deviation; WMA – wall motion abnormality 
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